Page 103 - Binder2

suppress unnecessary immune responses, building an
immunological “memory” of safety.

This is tolerance induction: a quiet, deliberate process by
which the immune system says,
"This is not a threat. This is part of the environment. Let’s
not waste energy attacking it."

And here’s the key: none of that happens during an
injection.

When a biologic is delivered subcutaneously or
intravenously, dendritic cells are still involved—but they
don’t receive the same cues. They operate in a different
context—one often associated with tissue damage or
pathogen invasion. The same antigen that would induce
Tregs in the gut may instead trigger an effector response in
the skin or bloodstream, leading to inflammation, antibody
production, and eventually, tolerization.

In other words, dendritic cells are not inherently
tolerogenic or inflammatory.
They’re interpreters. They respond to context. And the gut
provides the most tolerogenic context we know.

This is why the route of administration matters so much.
It’s not just about absorption or bioavailability—it’s about
the story we tell the immune system. And dendritic cells
are the editors.

Designing biologics for immune acceptance means
engaging this system directly. It means using the delivery
route that instructs dendritic cells to promote peace, not
war. And it means building therapies that don’t just pass
undetected—but are actively welcomed by the immune
architecture.

101